Neuroprotective Effects of Shiliuwei Kangchanzhijing Capsules in Rotenone‐Induced Parkinson's Disease Mouse Model: Involvement of the Parkin/PP2A/α‐Syn Pathway
Biomedical Chromatography · 2026
DOI: 10.1002/bmc.70320 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2026. Verfasst von Ying Ma und 4 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Neuroprotective Agents, Parkinson Disease. Die Arbeit nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Scientific Research Program of Universities in Anhui Province, Anhui Province 2023 Jianghuai Talent Cultivation Program Outstanding Project.
Abstract (Originalsprache)
Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by the loss of dopaminergic neurons in the substantia nigra and the pathological accumulation of α‐synuclein (α‐Syn). Rotenone, a mitochondrial complex I inhibitor, reliably reproduces these hallmark features and is therefore widely used to establish experimental PD models. Shiliuwei Kangchanzhijing capsules (SLW‐KCZJ capsules), a traditional Chinese medicine (TCM) formulation comprising 16 herbal components, were specifically developed for PD management. This study systematically evaluated the neuroprotective effects and underlying mechanisms of SLW‐KCZJ in a rotenone‐induced PD mouse model. SLW‐KCZJ treatment significantly improved movement distance and balance–coordination, attenuated neuronal loss in the substantia nigra, and markedly suppressed neuroinflammatory responses. At the molecular level, the capsules increased tyrosine hydroxylase expression by approximately 200% and elevated Parkin and protein phosphatase 2A levels by approximately 60% and 80%, respectively. In contrast, they robustly inhibited polo‐like kinase 2 expression and reduced α‐Syn levels by approximately 60% and 40%. The intervention also increased striatal dopamine (DA) and homovanillic acid levels while lowering neurofilament light chain and oligomeric α‐Syn. In summary, this study provides the first evidence that SLW‐KCZJ capsules exert neuroprotective effects by modulating the Parkin/PP2A/α‐Syn signaling pathway, offering a promising TCM‐based therapeutic strategy for PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China.
- Tianchang Hospital of Traditional Chinese Medicine, Tianchang, China.
- Anhui Provincial Key Laboratory of Chinese Medicinal Formula, Hefei, China.
ORCID-Profile: Ying Ma, Juan Zhang
Förderung
- National Natural Science Foundation of China
- Scientific Research Program of Universities in Anhui Province
- Anhui Province 2023 Jianghuai Talent Cultivation Program Outstanding Project
- Anhui Province Traditional Chinese Medicine High-Level Inheritance Talent Support Program
- Anhui University of Chinese Medicine Exploratory Research Project
- Foundation of Anhui Provincial Key Laboratory of Chinese Medicinal Formula
Zitieren
APA
Ma, Y., Yao, Y., Pu, Y., Chen, H., & Zhang, J. (2026). Neuroprotective Effects of Shiliuwei Kangchanzhijing Capsules in Rotenone‐Induced Parkinson's Disease Mouse Model: Involvement of the Parkin/PP2A/α‐Syn Pathway. Biomedical Chromatography. https://doi.org/10.1002/bmc.70320
Vancouver
Ma Y, Yao Y, Pu Y, Chen H, Zhang J. Neuroprotective Effects of Shiliuwei Kangchanzhijing Capsules in Rotenone‐Induced Parkinson's Disease Mouse Model: Involvement of the Parkin/PP2A/α‐Syn Pathway. Biomedical Chromatography. 2026. doi:10.1002/bmc.70320
BibTeX
@article{Ma2026,
author = {Ma, Ying and Yao, Yu and Pu, Yue and Chen, Hong and Zhang, Juan},
title = {Neuroprotective Effects of Shiliuwei Kangchanzhijing Capsules in Rotenone‐Induced Parkinson's Disease Mouse Model: Involvement of the Parkin/PP2A/α‐Syn Pathway},
journal = {Biomedical Chromatography},
year = {2026},
doi = {10.1002/bmc.70320}
}
EUVIMED